#
Writen by

Admin

Market Access Strategies for MENA Region Success

Winning market access across the Middle East & North Africa (MENA) means aligning (1) regulatory pathways, (2) pricing & tenders, (3) local stakeholder value, and (4) supply reliability—country by country. Below is a practical playbook with high-value moves and concrete references you can rely on.

1) Build your regulatory base, fast and digital

  • Anchor on primary authorities and formats.
    • KSA (Saudi Arabia): Register with SFDA and prepare for RSD serialization/track-and-trace integration across the supply chain. (Saudi Food and Drug Authority)
    • UAE: Online MoHAP registration; approvals typically valid 5 years; dossiers via eCTD; bilingual labeling. (Ministry of Health and Prevention – UAE)
    • Egypt: Follow EDA dossier guidance (CTD/eCTD structure) for registration and re-registration. (Egyptian Drug Authority)
    • Morocco: Submissions go to the DMP; MA review split across pharmacy division and national lab. (amrh.nepad.org)

Strategy tip: Standardize a core CTD/eCTD, then bolt on country-specific annexes (Arabic artwork, PV/QC steps, serialization specs). This avoids rework when timelines compress.

2) Price with the end buyer in mind (not just the regulator)

  • Know the rulebook, then work the route to purchase.
    • Saudi price governance: SFDA’s published Pricing Rules guide initial and renewal pricing (re-pricing considered at renewal). (Saudi Food and Drug Authority)
    • Egypt: Pricing evolved from cost-plus to external reference + mark-ups; procurement centralized under UPA (Law 151/2019). (ResearchGate)
    • Jordan: Regulated cumulative mark-ups are standard in private supply; understand how this flows through to retail. (EMRO Dashboards)
    • Morocco: Since 2013, Decree 2-13-852 enabled systematic price revisions; monitor periodic updates. (PMC)

Strategy tip: Model tender vs. retail net prices per country. A “compliant but uncompetitive” list price still loses if tenders (the real volume gate) demand deeper net positions.

3) Master the tendering landscape (public demand is concentrated)

  • KSA: NUPCO runs centralized procurement for public facilities (source-to-pay via inupco; check open competitions and the Unified Catalogue). (Nupco)
  • Egypt: UPA is the legally designated central buyer for government entities (Law 151/2019; Exec. Reg. 777/2020). (riad-riad.com)
  • UAE (Abu Dhabi): Supplier registration via the AD Government Procurement Gate (ADGPG) to access DoH opportunities. (Department of Health Abu Dhabi)

Strategy tip: Treat tender readiness as a commercial workstream—SKU qualification, pharmacoeconomic value framing, supply assurances, and service KPIs. Late paperwork = lost years.

4) Elevate value evidence (beyond clinical)

  • Regional payers are expanding HTA/MCDA use. Recent reviews across KSA, UAE, Qatar, and Egypt spotlight rising expectations for pharmacoeconomics and structured value assessment—still uneven, but growing. Build budget-impact and service models early. (PMC)
  • Localization & reliability count. In MENA, dependable in-stock performance, cold-chain integrity, and after-sales services can sway formulary and tender decisions as much as price.

Strategy tip: Pair your dossier with a payer pack (budget impact, pathway fit, real-world adherence/monitoring plan) tailored to each country’s procurement mechanics.

5) Country snapshots (what changes the outcome)

  • Saudi Arabia (SFDA / NUPCO)
  • United Arab Emirates (MoHAP / DoH/DHA)
  • Egypt (EDA / UPA)
    • What moves the needle: EDA dossier hygiene; UPA centralized purchasing; value messaging aligned to public-payer budget constraints. (Egyptian Drug Authority)
  • Jordan (JFDA)
    • What moves the needle: understanding regulated mark-ups and how they shape retail viability; private vs. institutional mix. (EMRO Dashboards)
  • Morocco (DMP)
    • What moves the needle: compliance with DMP registration flow; keep sight of post-2013 price-revision dynamics. (amrh.nepad.org)

6) Your MENA market-access operating plan (12–18 months)

Quarter 1–2: Foundation

  • Lock core CTD/eCTD and Arabic artwork; map serialization (RSD) and labeling by country. (Saudi Food and Drug Authority)
  • Build pricing corridors (list/reference/tender nets) with Morocco/Jordan mark-up math and KSA/Egypt tender scenarios. (EMRO Dashboards)

Quarter 3–4: First wins

  • Target one tender country (KSA or Egypt) and one retail-leaning country (e.g., UAE) to validate both routes to demand (tender + private/retail). (Nupco)
  • Submit to MoHAP/EDA and complete supplier registrations (ADGPG, UPA portals). (Department of Health Abu Dhabi)

Quarter 5–6: Scale & stabilize

  • Expand SKUs via NUPCO/UPA catalogues; incorporate pharmacoeconomic dossiers where asked; tighten service SLAs (fill rate, lead time, cold-chain). (Nupco)

7) KPIs that signal true access

  • Regulatory: approval lead-times; 1st-cycle approval rate; artwork/serialization right-first-time. (Saudi Food and Drug Authority)
  • Commercial: tender hit rate, awarded value, and on-contract service level (OTIF, in-temp). (Nupco)
  • Pricing: variance vs. corridor; re-pricing impact at renewal (KSA); Morocco price-revision outcomes. (Saudi Food and Drug Authority)
  • Access: formulary inclusions (UAE/DoH); regional availability index (stock-outs per 100 orders). (Department of Health Abu Dhabi)

8) Common pitfalls (and fixes)

  • Treating tenders as “after registration.” In KSA/Egypt, tender readiness drives volume—start months before approval. (Nupco)
  • One-size pricing. External reference rules + mark-ups + tender nets = different end-prices by channel; build country-specific net strategies. (EMRO Dashboards)
  • Underestimating labeling/serialization. Non-scannable codes or non-bilingual packs block release and payment. (Ministry of Health and Prevention – UAE)

Bottom line

Market access in MENA is won by pairing regulatory readiness (CTD/eCTD + serialization) with tender fluency (NUPCO/UPA) and payer-oriented value packs. Choose a beachhead (e.g., KSA tenders + UAE retail), prove reliability, then scale through catalogs and renewals while protecting price corridors.

Trusted references

  • Saudi FDA: RSD Track-and-Trace overview and service pages; Pharmaceutical Pricing Rules. (Saudi Food and Drug Authority)
  • UAE MoHAP: Registration service (5-year validity) and eCTD checklist. (Ministry of Health and Prevention – UAE)
  • Egypt EDA: Dossier requirements (registration & re-registration). UPA law and role in centralized procurement. (Egyptian Drug Authority)
  • Jordan: Mark-up/pricing context in public sources. (EMRO Dashboards)
  • Morocco: DMP process and post-2013 pricing reforms (Decree 2-13-852). (amrh.nepad.org)
  • Regional access & HTA trends: Peer-reviewed overview of procurement/reimbursement (KSA, UAE, Qatar, Egypt) and MCDA use. (PMC)

 

Admin